CorMedix Inc. (NASDAQ:CRMD) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET

Company Participants

Dan Ferry - LifeSci Advisors
Joe Todisco - CEO
Matt David - EVP and CFO
Liz Hurlburt - EVP and Chief Clinical Strategy and Operations Officer

Conference Call Participants

Anish Nikhanj - RBC Capital Markets
Jason Butler - Citizens JMP
Les Sulewski - Truist
John Juco - Needham & Company

Operator

Good day, and welcome to the CorMedix Inc. Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

I'd now like to turn the conference over to your host today, Daniel Ferry. Please go ahead.

Dan Ferry

Good morning, and welcome to the CorMedix second quarter 2024 earnings conference call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix and he is joined by Dr. Matt David, Executive Vice President and CFO; Beth Zelnick Kaufman, EVP and Chief Legal Officer; Liz Hurlburt, EVP and Chief Clinical Strategy and Operations Officer; and Erin Mistry, EVP and Chief Commercial Officer.

Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals and plans about the company's prospects and future financial position.

Actual results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CorMedix's filings with the SEC, which are available free of charge at the SEC's website or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in these forward-looking statements. Investors should not place undue reliance on these statements. CorMedix does not intend to update these forward-looking statements, except as required by law.

At this time, it's now my pleasure to turn the call over to Joe Todisco, Chief Executive Officer of CorMedix. Joe, please go ahead.

Joe Todisco

Thanks, Dan. Good morning, everyone, and thank you for joining us on this call.

As we reach the midpoint in the financial year, I'm incredibly pleased with the progress the company has made related to the launch of DefenCath, and I'm optimistic about the sales trajectory we have seen through only the first few weeks of the outpatient launch.